Marksans Pharma Ltd. has released its investor presentation for Q4FY26 and the full fiscal year 2026. The company reported a milestone year with ~₹3,000 crore in total income and ₹420 crore in Profit After Tax (PAT). Key highlights include strong revenue growth across major geographies like the US, UK, and Australia, driven by new product launches and strategic market expansion. The company also emphasized its robust manufacturing capabilities and a strong R&D pipeline.
Marksans Pharma Unveils Strong Q4 & FY26 Performance
Fiscal Year 2026: A Year of Milestones
Marksans Pharma Ltd. has announced its financial and business highlights for the fourth quarter and the full fiscal year ending March 31, 2026. The company achieved a milestone year with the highest-ever total income reaching approximately ₹3,000 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹601 crore, reflecting a margin of 20.4%, while the Profit After Tax (PAT) reached an all-time high of ₹420 crore.
Growth during FY26 was propelled by numerous product launches across various markets, including a notable expansion of its Rx branded portfolio in Australia. The UK market demonstrated a strong recovery, with Q4 achieving its highest-ever quarterly revenue. The US market also saw significant contributions with the launch of 112 new SKUs. Furthermore, Marksans has successfully expanded its global footprint by entering new markets such as Germany, Canada, and Ireland.
The company closed the fiscal year with a robust cash balance of approximately ₹990 crore, extending its multi-year track record of being net cash positive. The major capital expenditure cycle is now nearing completion.
Q4FY26 Performance Highlights
In the fourth quarter of FY26, Marksans Pharma reported Revenue of ₹856.1 crore, marking a 13.5% increase QoQ and a 20.8% increase YoY. The EBITDA margin expanded by 152 basis points QoQ to 22.8%, driven by operating leverage and tight cost control. Net profit growth outpaced EBITDA, reaching ₹149.0 crore, an increase of 31.1% QoQ, aided by favourable forex gains.
Geographical and Segmental Performance
US & North America remains the largest market, contributing ~52% of FY26 revenue with a significant 24% YoY growth to ₹1,533 crore. Revenue has scaled 2.4x from FY22 to FY26. The UK & Europe region contributed ₹1,015 crore (34.4% of revenue), with a 1.4% YoY growth. Australia & New Zealand showed strong growth of 19.9% YoY, reaching ₹303 crore (10.3% of revenue).
The company’s revenue is primarily driven by the OTC segment (80.0%), which has grown at a CAGR of 20.4% from FY17 to FY26. The Rx segment accounts for the remaining 20.0%.
Manufacturing and R&D Capabilities
Marksans Pharma operates multiple manufacturing facilities across the USA, UK, and India, with a total capacity of 26 billion units per annum. The company has a strong R&D focus, with 4 R&D centers and over 50 scientists. It boasts a pipeline of over 200 products and has secured 350+ ANDA/MA approvals.
Strategic Initiatives for Future Growth
The company’s core strategies for future growth are built on five pillars: a focus on store brand OTC segment, innovation and pipeline power, scale capacity and operating leverage, strategic acquisitions and front-end expansion, and sustainable and responsible growth.
Looking ahead, Marksans aims to become a top global consumer healthcare company with a multi-continent front-end direct presence and strong free cash flow generation. The growth roadmap includes expanding its presence in the US and North America, growing its EU front-end presence, and strengthening revenues in the UK and Canada.
Commitment to Sustainability
Marksans Pharma is committed to Environmental, Social, and Governance (ESG) principles. The company focuses on driving sustainable progress through initiatives in healthcare, education, environmental protection, and community empowerment. This includes organized health check-up camps, contribution to education, tree plantation drives, and ensuring overall wellbeing of women and children.
Strong Balance Sheet and Credit Rating
The company maintains a strong balance sheet with a cash balance of ₹990 crore as of March 31, 2026, and has been cash positive for over 5 years. It also holds a strong credit rating with CARE rating and India rating (Long term: CARE AA-; Stable, Short term: CARE A1+), indicating low financial risk.
Source: BSE
